Since the tyrosine kinase fusion protein serves as a pivotal driver of malignant cell proliferation in CML, the presence of the Philadelphia chromosome or BCR-ABL1 fusion remains the gold standard for diagnosing CML (9). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.